Navigation Links
2008 a Record Year for Gerresheimer

DUSSELDORF, Germany, April 29 /PRNewswire-FirstCall/ --

- Strong Focus on the Markets of Pharma & Life Science

- Annual General Meeting Passes Dividend of EUR0.40 per Share

The Annual General Meeting of Gerresheimer AG today passed an unchanged dividend of EUR0.40 per share following the record year in 2008.

The Company finished the financial year 2008 with record results. Gerresheimer achieved sales of EUR1.06 billion (prior year EUR957.7m) and operating results (adjusted EBITDA) of EUR206.4m (prior year EUR181.6m).

At the Annual General Meeting in Dusseldorf the CEO Dr. Axel Herberg summarized the highlights of the financial year 2008: "We have achieved record levels in terms of sales and earnings. Gerresheimer is on a good course and will show itself to be very robust even in times of crisis."

The shareholders approved the actions of the members of the Company's Supervisory Board and Management Board for the financial year 2008 and, as in the prior year, passed a dividend payment of EUR0.40 per share.

With share capital representation of 59.44% the Annual General Meeting passed the following resolutions:

ITEM 2: Appropriation of net earnings for the financial year 2008:

(99.99% of votes in favor)

ITEM 3: Approval of the actions of the Management Board members for the financial year 2008:

(100% of votes in favor)

ITEM 4: Approval of the actions of the Supervisory Board members for the financial year 2008:

(100% of votes in favor)

ITEM 5: Supplementary election to the Supervisory Board of Mr. Theodor Stuth, Auditor and Certified Tax Advisor, Neuss:

    (100% of votes in favor)
    ITEM 6: Election of the auditor for the financial year 2009:
    (99.99% of votes in favor)
    The speech is available on
    About Gerresheimer

Gerresheimer employs around 10,000 people in 42 locations in Europe, America and Asia. In the financial year 2008, worldwide sales totalled EUR1.06bn. The product portfolio ranges from pharma­ceu­tical vials made of glass and plastic through to complex drug-delivery systems for the pharma & life science industry. These include sterile syringes, inhalers and other system-based approaches for safe dosage and application of medications. The Group enjoys a leading position in markets which are characterised by high technical and regulatory barriers.(WKN: 587300)

    Contact Press

    Burkhard Lingenberg
    Director Corporate Communication & Marketing
    Phone +49-211-6181-250
    Fax   +49-211-6181-241

    Contact Investor Relations

    Anke Linnartz
    Director Corporate Investor Relations
    Phone +49-211-6181-314
    Fax   +49-211-6181-121

SOURCE Gerresheimer AG
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Globus Medical Announces Record 2nd Quarter 2007 Results
2. BioSpace Draws Record Crowd to Chicago Life Science Career Fair
3. CardioDynamics Receives FDA 510(k) Clearance for Innovative Clinical Parameters and Electronic Medical Record Compatibility
4. Neptune Reports Year End Financial Results - Neptune Records 18% Sales Increase and 43% EBITDA Increase in Year End Results
5. Monsanto Sees Record Sales in Fiscal Year 2007; Seeds and Traits Business Contributes to Strong Fourth Quarter and Year-End Results
6. Thermo Fisher Scientific Reports Record Third Quarter Revenues and Adjusted EPS and Raises Full-Year Guidance
7. China Biologic Products Reports Record Third Quarter 2007 Results
8. KV Pharmaceutical Company Reports Record Revenues for Fiscal 2008 Second Quarter and Six Months on a Preliminary Basis
9. The Female Health Company Reports Record Profit for Both Fourth Quarter and Fiscal Year 2007
10. Signalife Receives FDA Clearance for OTC Non-Prescription Event Recorder Device
11. Protalix BioTherapeutics Sets Record Date for Annual Meeting of Shareholders
Post Your Comments:
(Date:11/27/2015)... ... November 27, 2015 , ... Pittcon is pleased to ... presentations offered in symposia, oral sessions, workshops, awards, and posters. The core ... of applications such as, but not limited to, biotechnology, biomedical, drug discovery, environmental, ...
(Date:11/26/2015)... CHESHAM , England , November 26, ... Lightpoint Medical, an innovative medical device company specializing in ... Euro grant from the European Commission as part of the ... enabling the company to carry out a large-scale clinical trial ... -->      (Logo: , ...
(Date:11/25/2015)... 2015 2 nouvelles études permettent d ... les différences entre les souches bactériennes retrouvées dans la plaque ... êtres humains . Ces recherches  ouvrent une nouvelle ... en charge efficace de l,un des problèmes de ... .    --> 2 nouvelles études permettent ...
(Date:11/25/2015)... 2015  Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) ... CEO of Neurocrine Biosciences, will be presenting at the ... New York . .   ... 5 minutes prior to the presentation to download or ... will be available on the website approximately one hour ...
Breaking Biology Technology:
(Date:10/29/2015)... , Oct. 29, 2015  The J. Craig ... report titled, "DNA Synthesis and Biosecurity: Lessons Learned and ... Department of Health and Human Services guidance for synthetic ... 2010. --> --> ... also has the potential to pose unique biosecurity threats. ...
(Date:10/29/2015)... OXFORD, Connecticut , October 29, 2015 /PRNewswire/ ... "Company"), a biometric authentication company focused on the ... Wocket® smart wallet announces that StackCommerce, a leading ... will be featuring the Wocket® smart wallet on ... NXTD ) ("NXT-ID" or the "Company"), a ...
(Date:10/27/2015)... Oct. 27, 2015 Synaptics Inc. (NASDAQ: SYNA ... that Google has adopted the Synaptics ® ClearPad ... to power its newest flagship smartphones, the Nexus 5X ... --> --> Synaptics ... provide strategic collaboration in the joint development of next ...
Breaking Biology News(10 mins):